(MedPage Today) -- A strategy of sequential CD7 chimeric antigen receptor (CAR) T-cell therapy and haploidentical hematopoietic stem-cell transplantation (HSCT), without graft-versus-host disease (GVHD) prophylaxis, is a feasible approach…
Breast cancer is the second-most common cancer diagnosis for U.S. women, and the second-leading cause of female cancer deaths. In recent years, breast cancer treatments have improved significantly, thanks to targeted gene therapy and…
Immutep releases preliminary results from TACTI-003 trial showing promising outcomes for first-line treatment of HNSCC patients without PD-L1 expression. Final data expected in H1 CY2024.
The Church of the Eagle and the Condor (CEC) announced on Monday that it settled its lawsuits with the Departments of Justice, Homeland Security, Customs and Border Protection and the DEA to use ayahuasca in its religious ceremonies.
Just last month, England’s NHS ombudsman warned that cancer patients could be put at risk ‘because of over-stretched and exhausted health staff working in a system at breaking point’
Under an ambitious plan to tackle the country's 'cancer calamity', the NHS vowed in 2019 to diagnose 75 per cent of patients in the earliest stage by 2028.
Mayo Clinic researchers have used a new approach to chemotherapy to more than double the typical survival rate for patients with stomach cancer and peritoneal metastasis, which is cancer that has spread to the lining of the abdominal…
In a study of patients who smoked when they were diagnosed with laryngeal cancer, those who quit smoking before starting chemotherapy or radiation responded better to treatment, were less likely to need their voice boxes surgically removed…
The Drug Enforcement Administration (DEA) is arguing that a federal law giving seriously ill people the “right to try” investigational drugs doesn’t apply to controlled substances like psychedelics. The agency’s claim comes in a new brief…
Discover Novartis' FDA approval for Lutathera in pediatric patients with GEP-NETs, marking a pivotal milestone in treating this rare cancer. Explore its efficacy in combating SSTR+ tumors, backed by robust trial data.
The U.S. Food and Drug Administration (FDA) has approved the immunotherapy-boosting drug N-803, which is marketed under the brand name Anktiva, to be used in combination with the immunotherapy Bacillus Calmette-Guerin (BCG) for the…
The U.S. Food and Drug Administration has approved Genentech's Alecensa (alectinib) as adjuvant treatment following tumor resection in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).
A MAN “at death’s door” after running out of treatment options for leukaemia became the second person in the world to be offered an experimental cancer drug that eradicated traces of the disease in months.
A MAN “at death’s door” after running out of treatment options for leukaemia became the second person in the world to be offered an experimental cancer drug that eradicated traces of the disease in months.
A MAN “at death’s door” after running out of treatment options for leukaemia became the second person in the world to be offered an experimental cancer drug that eradicated traces of the disease in months.
The team of experts were researching prostate cancer when they discovered the new organ in the human body. Upon further investigation of 100 patients it was discovered near the nose
A chemotherapy alternative called immunotherapy is showing promise in treating cancer — and a new artificial intelligence tool could help ensure that patients have the best possible experience.